TC
TARS icon

Truvestments Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Truvestments Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.1K Sell
907
-2
-0.2% -$128 0.01% 504
2026
Q1 		$63.8K Hold
909
– – 0.01% 467
2025
Q4 		$74.4K Buy
909
+468
+106% +$34.9K 0.01% 388
2025
Q3 		$26.2K Buy
441
+83
+23% +$4.09K ﹤0.01% 544
2025
Q2 		$14.5K Buy
+358
New +$16.1K ﹤0.01% 593

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Truvestments Capital's TARS Position: Q2 2026 in Review

Truvestments Capital reduced its Tarsus Pharmaceuticals (TARS) stake by 0.22% in Q2 2026, selling an estimated $128 and leaving 907 shares worth $57.1K. The position accounts for 0.01% of the portfolio, ranked #504.

Truvestments Capital first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $74.4K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Truvestments Capital held 907 shares of Tarsus Pharmaceuticals worth $57.1K as of Q2 2026.
  • Truvestments Capital sold 2 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $128.
  • Tarsus Pharmaceuticals made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #504 holding.
  • Truvestments Capital first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Truvestments Capital's Tarsus Pharmaceuticals position peaked at $74.4K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.